SOURCE-LINKED STUDY SUMMARY
Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials.
Abstract summarizedQuality not appraised
- What was studied
- A prespecified pooled analysis combined individual patient data from two randomized placebo-controlled semaglutide trials in obesity-related HFpEF.
- Who / model studied
- Participants had obesity-related heart failure with preserved ejection fraction and symptomatic physical limitations; one trial included diabetes and the other excluded it.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- Semaglutide improved heart-failure symptoms and physical limitations and reduced body weight versus placebo, with effects largely consistent across examined subgroups.
- Limitations & context
- This was a pooled analysis of two trials with defined obesity-related HFpEF eligibility, which limits interpretation outside that population.
Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1016/s0140-6736(24)00469-0